Globus Medical (GMED) Stock Price, News & Analysis

Company Overview

Globus Medical, Inc. (NYSE: GMED) is a medical device company that develops, manufactures and markets musculoskeletal solutions for surgeons, hospitals and patients. Its primary focus is spinal surgery, supported by a portfolio of implants, instruments and enabling technologies designed to assist with procedures involving the cervical, thoracic and lumbar spine.

The company’s products include spinal fusion systems, interbody devices, deformity correction systems, biologics and surgical instruments. Globus Medical also offers technology for computer-assisted surgery, navigation and robotic applications, including its Excelsius platform. Following its combination with NuVasive in 2023, the company expanded its offerings in spine care and added complementary technologies, products and services for orthopedic and neurological procedures.

Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and international markets. The company markets its products through direct sales and independent distribution channels, working with surgeons and healthcare institutions to support complex spinal and musculoskeletal procedures.

Key Stats

• Today's Range: $73.12 to $74.54
• 50-Day Range: $73.61 to $88.48
• 52-Week Range: $54.15 to $101.40
• Volume: 1.49 million shs
• Average Volume: 1.07 million shs
• Market Capitalization: $9.96 billion
• P/E Ratio: 18.98
• Dividend Yield: N/A
• Price Target: $101.77
• Consensus Rating: Moderate Buy

Globus Medical Stock Analysis - MarketRank™

Globus Medical scored higher than 87% of companies evaluated by MarketBeat, and ranked 49th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Globus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 3 strong buy ratings, 9 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Globus Medical has a consensus price target of $101.77, representing about 37.1% upside from its current price of $74.21.

Amount of Analyst Coverage

Globus Medical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.02%

Earnings Growth

Earnings for Globus Medical are expected to grow by 8.02% in the coming year, from $4.99 to $5.39 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Globus Medical is 18.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.

Price to Earnings Ratio vs. Sector

The P/E ratio of Globus Medical is 18.98, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.98.

Price to Earnings Growth Ratio

Globus Medical has a PEG Ratio of 1.18. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Globus Medical has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.04% of the float of Globus Medical has been sold short.

Short Interest Ratio / Days to Cover

Globus Medical has a short interest ratio ("days to cover") of 6.53.

Change versus previous month

Short interest in Globus Medical has recently decreased by 2.67%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Globus Medical does not currently pay a dividend.

Dividend Growth

Globus Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.55

News Sentiment

Globus Medical has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Globus Medical this week, compared to 5 articles on an average week.

Search Interest

Only 9 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

MarketBeat Follows

6 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,176,000.00 in company stock.

Percentage Held by Insiders

18.38% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/11/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:GMED
• CIK: 1237831
• Web: www.globusmedical.com
• Phone: (610) 930-1800
• Fax: 610-930-2042
• Employees: 6,000
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Globus Medical: $101.77
• High Price Target: $123.00
• Low Price Target: $80.00
• Potential Upside/Downside: +37.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.91
• Trailing P/E Ratio: 18.98
• Forward P/E Ratio: 14.87
• P/E Growth: 1.18
• Net Income: $537.87 million
• Net Margins: 17.02%
• Pretax Margin: 20.99%
• Return on Equity: 14.57%
• Return on Assets: 12.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.62
• Quick Ratio: 2.93

Sales & Book Value

• Annual Sales: $2.94 billion
• Price / Sales: 3.39
• Cash Flow: $6.34 per share
• Price / Cash Flow: 11.71
• Book Value: $33.86 per share
• Price / Book: 2.19

Miscellaneous

• Outstanding Shares: 134,260,000
• Free Float: 109,585,000
• Market Cap: $9.96 billion
• Optionable: Optionable
• Beta: 0.95